01 Open CGM Connectivity Is Reshaping Smart Insulin Delivery The market is shifting toward interoperable systems that connect insulin pumps and smart pens with different continuous glucose monitors. Earlier devices often operated within closed manufacturer ecosystems, limiting choice when users changed sensors or delivery products. Open connectivity allows dosing algorithms to receive glucose data from compatible third-party devices and gives healthcare teams a more complete treatment record. Manufacturers are therefore investing in standardized communication, smartphone applications, cloud reporting, and automated dose adjustment. This transition is making compatibility an important purchasing factor and encouraging partnerships between insulin-delivery and glucose-monitoring companies. In April 2025, Medtronic submitted an interoperable insulin-pump application to the U.S. FDA as part of its collaboration with Abbott on integrated glucose sensing.
01 Growing Diabetes Burden Expands the Insulin-Management Population The rising number of people living with diabetes is increasing demand for accurate and convenient insulin-delivery technologies. Patients using multiple daily injections must track doses, timing, meals, and glucose readings, creating opportunities for connected pens that automatically record injection information. Pump systems further support users who require continuous delivery and frequent dose adjustment. Healthcare providers also benefit from digital records that help identify missed doses and review treatment patterns between appointments. As diabetes care expands across hospitals, clinics, and homes, manufacturers can supply devices, disposable components, software subscriptions, and data-management services.
01 High Continuing Costs Limit Access to Connected Insulin Devices Smart insulin systems can create costs beyond the initial purchase. Pump users require infusion sets, reservoirs, wearable pods, sensors, and replacement accessories, while some platforms depend on compatible smartphones and paid digital services. These recurring expenses can make continued use difficult where insurance coverage is limited or patients face high personal payments. Healthcare providers must also complete documentation, training, and technical-support activities before prescribing advanced systems. Consequently, conventional insulin pens may remain the practical option for cost-sensitive patients, particularly in lower-income regions. Manufacturers must reduce ownership costs and simplify reimbursement to reach a wider population.
01 Type 2 Diabetes Clearance Opens a Larger Pump User Segment Automated insulin-delivery systems are moving beyond their traditional focus on type 1 diabetes. Some adults with type 2 diabetes require intensive insulin treatment but continue using several injections each day. Pumps connected to glucose sensors can adjust background delivery and support correction doses through an integrated algorithm. Regulatory clearance for this population gives manufacturers access to a much larger potential customer base and encourages diabetes clinics to establish new training programs. Companies that provide simple onboarding, compact devices, and remote clinical reports are well positioned to capture demand from adults moving from injections to automated delivery.
01 Software Failures and Missed Alerts Increase Safety Responsibilities Smart pumps depend on software, wireless connections, glucose sensors, and smartphone notifications working together correctly. A failure in any part of this chain can interrupt information used for insulin-management decisions. Manufacturers must continually test applications across changing phone models and operating systems while delivering security patches without disrupting device performance. Recall management is also difficult because users may depend on the affected product every day and require clear replacement instructions. These risks increase post-market monitoring, customer support, and regulatory responsibilities, making reliable software management as important as the mechanical design of the pump.
June 2026 Insulet Corporation began the U.S. rollout of an enhanced Omnipod® 5 Automated Insulin Delivery System, introducing a new algorithm with a 100 mg/dL glucose target and expanding compatibility with Abbott's FreeStyle Libre 3 Plus continuous glucose sensor. The launch strengthens Insulet's connected diabetes ecosystem and broadens sensor choice for users.
June 2026 Medtronic and Abbott expanded their global strategic partnership through an amended integration, supply, and distribution agreement to commercialize dual glucose-ketone sensors designed to integrate exclusively with Medtronic's MiniMed automated insulin delivery and Smart MDI systems.
June 2025 Tandem Diabetes Care and Abbott entered into a strategic development and commercialization agreement to integrate Tandem's automated insulin delivery systems with Abbott's future dual glucose-ketone sensor. The collaboration aims to provide advanced diabetes-management solutions capable of detecting rising ketone levels alongside glucose monitoring.